Our results in pediatric ALL patients receiving HD-MTX doses have shown that the possibility for having one additional low clearance episode increases by 40% with each A allele of SLC19A1.c80 variant. This evidence concerns the gene SLC19A1 and acute lymphoblastic leukemia.